A Phase 4 interventional study of Verteporfin for injection in Age-Related Macular Degeneration, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2006-06-21.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing verteporfin in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Verteporfin · Macular Degeneration.
Among the 18 studies testing verteporfin in Macular Degeneration, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2003, is one of 6 in phase 4, and was the 2nd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →None of the 18 studies testing verteporfin in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →
Verteporfin: first FDA approval 2000 (VISUDYNE), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 60 across the 17 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 22nd largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2003, is one of 18 in phase 4, and was the 1st registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing verteporfin in Macular Degeneration, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
visual acuity measurements, baseline, 12 months
visual acuity measurements, fundus photographs and fluorescein angiography at baseline, 12 months; ophthalmic examinations, adverse events, vital signs, concomitant medications, 12 months
This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verteporfin